Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?

Health Policy

Volumn 119, Issue 2, 2015, Pages 212-216

  Garattini, Livio ^a   van de Vooren, Katelijne ^a   Curto, Alessandro ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Biosimilars; Economic evaluation; Health technology assessment; Metastatic breast cancer; Trastuzumab

Indexed keywords

BIOSIMILAR AGENT; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EUROPE; HUMAN; INFORMATION RETRIEVAL; QUALITY OF LIFE; REIMBURSEMENT; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAST NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; EUROPEAN UNION; FEMALE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG COSTS; EUROPEAN UNION; FEMALE; HUMANS; QUALITY OF LIFE; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84922802314     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2014.12.002     Document Type: Article

References (33)

1. Cancer Research UK. [accessed 28.05.14]. http://www.cancerresearchuk.org/cancerinfo/cancerstats/types/breast/incidence/uk-breast-cancer-incidence-statistics#world.
2. WHO. Cancer. [accessed 28.05.14]. http://www.who.int/cancer/detection/breastcancer/en/.
3. Butters D.J., Ghersi D., Wilcken N., Kirk S.J., Mallon P.T. Addition of drugs to a chemotherapy regimen for metastatic breast cancer. Cochrane Database of Systematic Reviews 2010, (11). Art. No. CD003368.
4. Noonberg S.B., Benz C.C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily role as anticancer agents. Drugs 2000, 59(April):753-767.
5. Leopold C., Vogler S., Habl C., Mantel-Teeuwisse A.K., Espin J. Personalised medicine as a challenge for public pricing and reimbursement authorities - a survey among 27 European countries on the example of trastuzumab. Health Policy 2013, 113(December):313-322.
6. GaBI. US$54 billion worth of biosimilar patents expiring before 2020.
7. Cortes J., Curigliano G., Dieras V. Expert perspectives on biosimilar monoclonal antibodies in breast Cancer. Breast Cancer Research and Treatment 2014, 144(April):233-239.
8. Curto S., Ghislandi S., van de Vooren K., Duranti S., Garattini L. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices. Health Policy 2014, 116(June):182-187.
9. Velasco Garrido M., Kristensen F.B., Nielsen C.P., Busse R. Health technology assessment and health policy-making in Europe 2008, WHO/European Observatory on Health Systems and Policies, Copenhagen/Brussels.
10. Anderson R. Systematic reviews of economic evaluations: utility or futility?. Health Economics 2010, 19(March):350-364.
11. De Pouvourville G., Ulmann P., Nixon J., Boulenger S., Glanville J., Drummond M. The diffusion of health economics knowledge in Europe. The EURONHEED (European Network of Health Economic Evaluation Databases) Project. Pharmacoeconomics 2005, 23(2):113-120.
12. EMA. Herceptin.
13. Elkin E.B., Weinstein M.C., Winer E.P., Kuntz K.M., Schnitt S.J., Weeks J.C. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost effectiveness analysis. Journal of Clinical Oncology 2004, 22(March):854-863.
14. Parkinson B., Pearson S., Viney R. Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique. The European Journal of Health Economics 2014, 15(January):93-112.
15. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine 2001, 344(March):783-792.
16. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Clinical Oncology 2005, 23(July):4265-4274.
17. Chen T., Xu T., Li Y., Liang C., Chen J., Lu Y., Wu Z., Wu S. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treatment Reviews 2011, 37(June):312-320.
18. Rugo H., Brammer M., Zhang F., Lalla D. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clinical Breast Cancer 2010, 10(August):288-293.
19. Osoba D., Slamon D.J., Burchmore M., Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. Journal of Clinical Oncology 2002, 20(July):3106-3113.
20. Duthie K., Bond K. Improving ethics analysis in health technology assessment. International Journal of Technology Assessment in Health Care 2011, 27(January):64-70.
21. Garattini L., Van de Vooren K., Curto A. Regional HTA in Italy: promising or confusing?. Health Policy 2012, 108(December):203-206.
22. Buiting H.M., Terpstra W., Dalhuisen F., Gunnink-Boonstra N., Sonke G.S., den Hartogh G. The facilitating role of chemotherapy in the palliative phase of cancer: qualitative interviews with advanced cancer patients. PLOS ONE 2013, 8(11):e77959.
23. Norum J., Risberg T., Olsen J.A. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Annals of Oncology 2005, 16(June):909-914.
24. Lidgren M., Wilking N., Jönsson B., Rehnberg C. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncologica 2008, 47:1018-1028.
25. Poncet B., Bachelot T., Colin C., Ganne C., Jaisson-Hot I., Orfeuvre H., et al. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. American Journal of Clinical Oncology 2008, 31(August):363-368.
26. Perez-Ellis C., Goncalves A., Jacquemier J., Marty M., Girre V., Roché H., et al. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer. American Journal of Clinical Oncology 2009, 32(October):492-498.
27. Lidgren M., Jönsson B., Rehnberg C., Willking N., Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Annals of Oncology 2008, 19(March):487-495.
28. Lidgren M., Wilking N., Jönsson B., Rehnberg C. Health related quality of life in different states of breast cancer. Quality of Life Research 2007, 16(August):1073-1081.
29. Technology Appraisal No. 34 Guidance on the use of trastuzumab for the treatment of advanced breast cancer. NICE [accessed 28.05.14]. http://publications.nice.org.uk/guidance-on-the-use-of-trastuzumab-for-thetreatment-of-%20advanced-breast-cancer-ta34.
30. Farfan-Portet M.I., Gerkens S., Lepage-Nefkens I., Vinck I., Hulstaert F. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?. The European Journal of Health Economics 2014, 15(April):223-228.
31. EMA. Kadcyla.
32. National Institute for Health and Care Excellence Draft guidance on trastuzumab emtansine (after trastuzumab and a taxane) for HER2 positive, unresectable, metastatic breast cancer 2014, April, http://guidance.nice.org.uk/TAG/350 [accessed 28.05.14].
33. ® 2013, July, http://www.pbs.gov.au/info/industry/listing/elements/pbacmeetings/psd/2013-07/trastuzumab-emtansine [accessed 28.05.14].